Table 3 Adverse events (treatment-related)
Adverse events | SOX+B-mab (n = 22) | SOX+C-mab (n = 23) | ||
|---|---|---|---|---|
All grades (%) | ≧Grade 3 (%) | All grades (%) | ≧Grade 3 (%) | |
Hematologic adverse events | ||||
 Leucopenia | 3 (13.6) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
 Anemia | 7 (31.8) | 1 (4.8) | 6 (26.1) | 1 (4.3) |
 Thrombocytopenia | 6 (27.2) | 1 (4.8) | 8 (34.8) | 3 (13.0) |
 Hyperbilirubinemia | 8 (36.4) | 2 (9.1) | 4 (17.4) | 0 (0.0) |
 Hypoalbuminemia | 6 (27.2) | 1 (4.8) | 7 (30.4) | 0 (0.0) |
 Aspartate aminotransferase increased | 6 (27.2) | 0 (0.0) | 8 (34.8) | 1 (4.3) |
 Alanine aminotransferase increased | 6 (27.2) | 0 (0.0) | 9 (39.1) | 1 (4.3) |
 Hypomagnesemia | 1 (4.8) | 0 (0.0) | 1 (4.3) | 0 (0.0) |
 Hyperkalemia | 1 (4.8) | 0 (0.0) | 3 (13.0) | 0 (0.0) |
Nonhematologic adverse events | ||||
 Mucositis oral | 4 (18.2) | 0 (0.0) | 6 (26.1) | 0 (0.0) |
 Nausea | 3 (13.6) | 0 (0.0) | 5 (21.7) | 0 (0.0) |
 Vomiting | 1 (4.8) | 0 (0.0) | 5 (21.7) | 1 (4.3) |
 Diarrhea | 5 (22.7) | 1 (4.8) | 11 (43.5) | 2 (8.7) |
 Anorexia | 9 (40.9) | 2 (9.1) | 9 (39.1) | 2 (8.7) |
 Fatigue | 3 (13.6) | 2 (9.1) | 5 (21.7) | 0 (0.0) |
 Malaise | 7 (31.8) | 1 (4.8) | 9 (39.1) | 0 (0.0) |
 Allergic reaction | 0 (0.0) | 0 (0.0) | 2 (8.7) | 0 (0.0) |
 Peripheral sensory neuropathy | 18 (81.8) | 2 (9.1) | 16 (69.6) | 0 (0.0) |
 Peripheral motor neuropathy | 3 (13.6) | 0 (0.0) | 2 (8.7) | 0 (0.0) |
 Palmar-plantar erythrodysesthesia syndrome | 2 (9.1) | 0 (0.0) | 4 (17.4) | 0 (0.0) |
 Proteinuria | 3 (13.6) | 0 (0.0) | 3 (13.0) | 0 (0.0) |
 Hypertension | 3 (13.6) | 0 (0.0) | 2 (8.7) | 1 (4.3) |
 Skin and subcutaneous tissue disorders | 1 (4.8) | 0 (0.0) | 12 (52.2) | 0 (0.0) |
 Paronychia | 0 (0.0) | 0 (0.0) | 10 (43.5) | 0 (0.0) |
Total | 20 (90.9) | 10 (45.6) | 23 (100) | 11 (47.8) |